OBJECTIVES: The abuse of benzodiazepines and Z-drugs reduces the quality of life of millions of addicted people worldwide. They cannot be discontinued abruptly due to harmful withdrawal symptoms. Detoxification is usually based on replacement of short/middle acting benzodiazepines or Z-drugs by diazepam and tapering the dose over time. In order to enhance patient adherence to an individual withdrawal plan, suitable diazepam dosage forms have to be available. Hard capsules containing an exact and uniform dose could be used for the relief of symptoms caused by altering the plasma level and overcoming psychogenic stress from the dose reduction. METHODS: This work demonstrates that capsules with a content of diazepam ranging from 2.125mg to 0.492 mg (dose decreasing always by 15%) cannot be easily prepared by standard mortar technology in a pharmacy. To meet mass and content uniformity European Pharmacopoeia criteria, capsules were prepared by improved technology based on the preparation of binary blends of calcium phosphate anhydrous and diazepam in descending concentrations in a high-speed mixer (time 30 s) and densification of about 10% during filling of the capsules. RESULTS: All batches (n=20) prepared by improved technology met the requirement for content uniformity compared with only nine batches prepared by standard mortar blender technology. Based on the process capability index, none of the samples prepared by standard technology fitted pharmacopeia limits at the statistically acceptable level. On the other hand, all batches prepared by improved technology exhibited acceptable process capability index. CONCLUSIONS: We have shown that at least 99.73% of batches prepared by our improved technology would meet the pharmacopoeia limits for content uniformity and are suitable for treatment of this type of addiction.

Department of Applied Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Department of Chemical Drugs University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Department of Pharmaceutics University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Zobrazit více v PubMed

Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005;18:249–55. 10.1097/01.yco.0000165594.60434.84 PubMed DOI

Smith DE, Wesson DR. The benzodiazepines: current standards for medicalpractice. Dordrecht: Springer Netherlands, 1985:159–63.

Tyrer P. Benzodiazepine substitution for dependent patients—going with the flow. Addiction 2010;105:1875–6. 10.1111/j.1360-0443.2010.03067.x PubMed DOI

Lugoboni F, Mirijello A, Faccini M, et al. . Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend 2014;142:105–9. 10.1016/j.drugalcdep.2014.06.020 PubMed DOI

Szelenberger W, Soldatos C. Sleep disorders in psychiatric practice. World Psychiatry 2005;4:186–90. PubMed PMC

Hibell B, Guttormsson U, Ahlström S, et al. ; Summary 2011 ESPAD report: substance use among students in 36 European countries. European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Publications Office of the European Union, 2012.

Salzman C. Benzodiazepine dependence, toxicity, and abuse: a task force report of theAmerican Psychiatric Association. Am J Psychiatry 1991;148:151–2. PubMed

Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr 2015;38:152–5. 10.18773/austprescr.2015.055 PubMed DOI PMC

Ashton H. How to withdraw from benzodiazepines after long-term use. http://www.benzo.org.uk/manual/bzcha02.htm

Rickels K, Case WG, Schweizer E, et al. . Benzodiazepine dependence: management of discontinuation. Psychopharmacol Bull 1990;26:63–8. PubMed

Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. J Clin Psychiatry 1993;54:189–91. PubMed

Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol 2014;77:295–301. 10.1111/j.1365-2125.2012.04418.x PubMed DOI PMC

Benyamina A, Naassila M, Bourin M. Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal. Psychiatry Res 2012;198:307–12. 10.1016/j.psychres.2012.01.009 PubMed DOI

Cantopher T, Olivieri S, Cleave N, et al. . Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry 1990;156:406–11. 10.1192/bjp.156.3.406 PubMed DOI

Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm 2011;404:1–9. 10.1016/j.ijpharm.2010.11.001 PubMed DOI

Newton DW, Schulman SG, Becker CH. Limitations of compounding diazepam suspensions from tablets. Am J Hosp Pharm 1976;33:450–2. PubMed

Franc A. Možnosti individualizované přípravy léků v oblasti léčby lékových závislostí. dny farmaceutické péče V – individualizovaná péče o pacienta. (In Czech). Czechia: VFU Brno, 25-26 September 2015. https://faf.vfu.cz/FaF/informace-o-fakulte/aktuality/dny-farmaceuticke-pece-2015.pdf

Kornchankul W, Hamed E, Parikh NH, et al. . Effect of drug proportion and mixing time on the content uniformity of a low dose drug in a high shear mixer. Pharmazie 2002;57:49–53. PubMed

Muselík J, Franc A, Doležel P, et al. . Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP. Acta Pharm 2014;64:355–67. 10.2478/acph-2014-0022 PubMed DOI

Jales STL, Soares-Sobrinho JL, Nunes LCC, et al. . Formulation technology of a probiotic (Zymomonas mobilis) in gelatinous capsules. Lat Am J Pharm 2007;26:553–7.

Commercially Available Enteric Empty Hard Capsules, Production Technology and Application